Navigation Links
Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi
Date:6/26/2008

Quark's second siRNA drug delivered systemically

FREMONT, Calif., June 25 /PRNewswire/ -- Quark Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for its siRNA drug candidate, DGFi, in kidney transplantation. The Company expects its Phase I/II clinical study for prevention/treatment of Delayed Graft Function (DGF) in kidney transplant patients to begin in the second half of 2008.

DGFi is Quark's second product candidate to enter clinic trials that is systemically administered to patients. The first ever siRNA drug candidate to be delivered systemically in man was Quark's AKIi-5 which is in Phase I clinical trial for acute kidney injury.

The Phase I/II will be a multi center study in which the safety and tolerability of escalating doses of DGFi by a single IV injection in renal transplant patients with DGF. Up to 204 adult kidney transplant recipients will be enrolled in this 2-part study.

"We are pleased with the FDA acceptance of our DGFi IND application for prevention of delayed graft function, which is a very serious medical issue for kidney transplant patients," said Shai Erlich, Ph.D., Chief Development Officer of Quark. "This is an important milestone for us. It marks Quark's third clinical program and the second in which our siRNA drug is administered systemically to patients. This achievement provides further validation of Quark's RNAi based drug discovery approach."

About DGF and Kidney Transplant

Delayed Graft Function (DGF) in renal transplantation is a syndrome caused by ischemia and reperfusion injury. Ischemia reperfusion injury occurs frequently in kidneys that have been outside a living human body and damaged from lack of oxygen in the kidneys that have been blood deprived. In patients with DGF the transplanted kidney does not function properly and requires intervention by dialysis.


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 04, 2015 The print component of ... San Francisco Chronicle with a circulation of approximately 173,000 ... digital component is distributed nationally through a vast social ... sites and partner outlets. To explore the digital version ... Milorganite is composed of heat-dried microbes that have digested ...
(Date:3/4/2015)... Houston, Texas (PRWEB) March 04, 2015 ... blog , Endometriosis can be a painful ... endometrium) starts spreading outside of the uterus leading to ... and their families. Endometriosis can have a terrible effect ... symptoms. It is also the most common cause of ...
(Date:3/4/2015)... March 04, 2015 The popular all-natural ... their new L-Style Revolution™ Program. The customized program provides ... women of all health and fitness levels to follow ... faster than traditional methods. , “We’re really proud to ... plans based on award winning techniques to help people ...
(Date:3/4/2015)... California (PRWEB) March 04, 2015 RapidScale, ... 2015, in Las Vegas, Nevada, on March 16th-18th. They ... RapidScale will have some of its top engineering executives ... advances in the RapidScale solution set. Attendees include William ... Senior Cloud Engineer; and Ryan Turpin, Cloud Support Manager. ...
(Date:3/4/2015)... 2015 SIGVARIS proved innovative ... their first compression therapy collection designed exclusively for men. ... SIGVARIS USA is proud to announce the launch of ... , Constructed from a unique, extremely fine synthetic fiber, ... These socks and thigh-highs offer a tailored look that ...
Breaking Medicine News(10 mins):Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 3Health News:The Makers of Liporidex, The Popular Sports Nutrition Supplement Brand, Launches Its New L-Style Revolution™ Diet & Exercise Program That Promises Turbo Charged Results 2Health News:Rapidscale to Host First Cloudtalk Events at Channel Partners in Las Vegas 2Health News:Rapidscale to Host First Cloudtalk Events at Channel Partners in Las Vegas 3Health News:Building on the Success of MIDTOWN MICROFIBER, SIGVARIS Expands Popular Compression Collection with Longer Foot Length Offerings 2
... 90-Day Supply of More Than 400,Generic Drugs for ... WOONSOCKET, R.I., Oct. 30 Today,CVS/pharmacy, the ... care savings program aimed at helping the uninsured ... obtain a,CVS/pharmacy Health Savings Pass for a $10 ...
... clocks to summer time on the last Sunday in March ... In return, putting the clocks back in the autumn reduces ... a new Swedish study published in the prestigious New ... have examined how the incidence of myocardial infarction in Sweden ...
... and ... Milk Their Diets, HOUSTON, Oct. 30 The last decade ... seem to go in and out of,fashion like shoulder pads and hemlines. Yet, ... Texas residents --,remain overweight or obese., A new campaign crossing the country, ...
... TeleHealth Services, Inc., a,leading provider of integrated communication ... Barker to the new position of Director of,Marketing. ... research and analysis., After a comprehensive search, ... efforts for its comprehensive line of integrated,hospital television ...
... Arno Therapeutics,Inc. (OTC Bulletin Board: ARNI.OB), a ... the appointment,of William F. Hamilton, Ph.D. to its ... committee. Dr. Hamilton has over 40 years experience ... expertise in the areas of,technology strategy and planning, ...
... by Dr. David Katz, Director of Yale University,s,Prevention Research Center ... in Blood Pressure -, DERBY, Conn., Oct.30 Snacking ... help with weight control, according to a recently,completed pilot study ... overweight adults consumed two KIND Fruit & Nut Delight,Bars per ...
Cached Medicine News:Health News:CVS/pharmacy Announces Pharmacy Health Care Savings Program Targeted at the Uninsured 2Health News:CVS/pharmacy Announces Pharmacy Health Care Savings Program Targeted at the Uninsured 3Health News:Clock-shifts affect risk of heart attack 2Health News:Message to Houston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Houston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:TeleHealth Names Matthew K. Barker to New Director of Marketing Position 2Health News:Arno Therapeutics Appoints William F. Hamilton to Board of Directors 2Health News:Arno Therapeutics Appoints William F. Hamilton to Board of Directors 3Health News:Daily Snack Bars May Facilitate Weight Loss 2Health News:Daily Snack Bars May Facilitate Weight Loss 3Health News:Daily Snack Bars May Facilitate Weight Loss 4
(Date:3/4/2015)... N.Y. , March 4, 2015  Kannalife Sciences, ... MD has joined its Scientific Advisory Board to assist ... development efforts towards the use of cannabinoid therapeutics for ... is the forensic pathologist responsible for conducting the full ... Hall of Fame center for the Pittsburgh Steelers. It ...
(Date:3/4/2015)... Mar. 04, 2015 Research and Markets ... of the "Negative Pressure Wound Therapy Market ... Industry Analysis, Size, Share, Growth, Trends and Forecast ... , The global negative pressure ... and by geography. By product types the NPWT ...
(Date:3/4/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery ... the upcoming 27 th Annual ROTH Conference, taking ... CA.  Dr. Michael Berelowitz , Chairman ... a corporate overview on March 10, 2015. ...
Breaking Medicine Technology:Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 2Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 3Global Negative Pressure Wound Therapy (Conventional and Single Use NPWT Systems) Market Report 2014-2020 2Oramed to Present at the ROTH Conference 2Oramed to Present at the ROTH Conference 3
... HIGHLIGHTS:2011 Results (all percentages are to ... reported sales increased 11% to $626 million. Q3 sales grew ... sales growing organically by 4% and 2%, respectively.  Recently completed ... exchange rates contributed an additional 5% to reported sales growth ...
... Merz Pharmaceuticals, LLC, today announced that data from ... Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from ... will be presented at the 115th Annual Meeting of ... These data include an extension of the ...
Cached Medicine Technology:Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 2Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 4Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 5Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 6Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 7Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 8Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 9Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 10Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 11Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 12Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 13Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 2Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 3Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 4Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 5Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 6Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 7Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 8
... Implants - Anatomically designed to enhance the chin ... the mandible with a high-profile central chin projection. ... the entire mandible, this implant provides a high ... extended arms. Cleft Chin Implants - Designed ...
... FL40 Centrifuge Series from Thermo Electron ... increase your productivity in the lab. ... rotors and accessories for high-volume blood ... IEC CL40 and FL40 Centrifuge Series ...
... Multispeed Series offers unsurpassed versatility and ... 1.2 liter benchtop centrifuge. With its ... and high-speed centrifugation capabilities, the IEC ... need to meet a variety of ...
... CL30 Series from Thermo delivers ... for your low-speed clinical applications. ... exchange system, user-friendly controls, and ... CL30 Series delivers solid performance ...
Medicine Products: